Please login to the form below

Not currently logged in
Email:
Password:

MEDI1814

This page shows the latest MEDI1814 news and features for those working in and with pharma, biotech and healthcare.

Biogen rises on more positive data for Alzheimer's candidate

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,

Latest news

  • Lilly taps AstraZeneca for another anti-amyloid drug Lilly taps AstraZeneca for another anti-amyloid drug

    Lilly and AZ will collaborate on the development of MEDI1814, an antibody against amyloid-beta 42 (Aβ42), which is currently in phase I trials. ... MEDI1814 dose-dependently reduces levels of the Aβ42 peptide - which is thought to be particularly

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics